TVTX - Company ID 0001438533
The table below shows Travere Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $127.20M | $164.86M | $114.45M | $81.73M | $62.90M | $54.12M |
| Cost of revenue | $1.95M | $1.58M | $1.52M | $4.68M | $1.63M | $2.06M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
Travere Therapeutics, Inc. reported annual revenue of $490.73M for fiscal year 2025. That is up 110.5% from $233.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.59M (FY 2016) to $490.73M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $80.25M |
| $86.45M |
| $76.22M |
| $60.41M |
| $65.62M |
| $64.78M |
| Operating income | -$36.91M | $24.93M | -$12.65M | -$42.67M | -$56.15M | -$67.70M |
| Income tax | -$120.00K | $8.00K | $20.00K | $39.00K | -$84.00K | $85.00K |
| Net income | -$37.10M | $25.71M | -$12.76M | -$41.23M | -$54.81M | -$70.41M |
| EPS (diluted) | -$0.40 | $0.28 | -$0.14 | -$0.47 | -$0.70 | -$0.91 |